Coreline Soft and Mint Medical Announce Partnership to Advance AI-Enabled Lung Cancer Screening

The partnership supports an end-to-end workflow connecting AI-powered pulmonary nodule detection, multi-disease analysis, structured reporting, longitudinal nodule tracking, and multi-site reading management. While initially focused on Germany, where LDCT-based lung cancer screening entered statutory health insurance reimbursement in April 2026, the collaboration is designed to scale across international markets where structured and operationally rigorous screening programs are emerging.
 
Germany's national screening framework requires double reading by independent institutions, CAD software utilization, longitudinal follow-up, quality assurance, and GDPR-compliant multi-site data management. In this context, AI's role has evolved from optional decision support to operational necessity. What hospitals now require is not simply a high-performing algorithm, but an integrated workflow that connects detection, structured reporting, and follow-up into a reliable, scalable system. This collaboration is built to meet that requirement — and to serve as a replicable model for other national programs adopting similar standards.



"With the integration of Coreline Soft's AI solution into mint Lesion, we are specifically addressing the requirements of lung cancer screening and enabling scalable, quality-assured workflows, longitudinal follow-up, and optimized interaction with AI results. Coreline Soft contributes an established and clinically validated solution that complements our structured reporting workflows very well. The partnership also allows us to bring the full workflow to our markets in a consolidated way and provide hospitals with seamless access."
 — Onur Özek, Managing Director, Mint Medical

 “Coreline Soft has developed AI that goes beyond pulmonary nodule detection, analyzing lung cancer, COPD, and coronary artery calcification from a single chest CT through opportunistic analysis. Mint Medical’s mint Lesion platform connects those AI-derived findings to structured reporting and longitudinal patient management, which is exactly what Germany’s national screening infrastructure demands. When detection, structured reporting, and follow-up management are joined in a single operational flow, AI becomes the infrastructure that transforms how a healthcare system operates.”
 — Jin-Kook Kim, CEO, Coreline Soft

 Coreline Soft's AVIEW has been applied in over 2.5 million real-world clinical reads across hospitals in 19 countries, and is the adopted AI solution in major lung cancer screening initiatives including HANSE (Germany), IMPULSION (France), and RISP (Italy).
 Through the mint Lesion platform, partner technologies are incorporated directly into the radiologist’s reading process, supporting standardized data collection from medical images. The open environment allows radiologists to utilize AI-augmented third-party applications while documenting findings in a structured format.
 The integration of AVIEW into mint Lesion is designed to enable AI-detected lung nodule findings to be incorporated into structured reporting workflows, supporting Lung-RADS classifications, volume doubling time (VDT) calculations, and follow-up planning. This helps reduce manual workload and improve consistency across multi-site lung cancer screening operations.